Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein

Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells

(2010) Dominik Fuchs et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor

(2010) Roberta Riccioni et al.   BLOOD CELLS MOLECULES AND DISEASES

High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers

(2010) See-Hyoung Park et al.   CANCER BIOLOGY & THERAPY

SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin

(2009) Ju-Hwa Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells

(2009) Dominik Fuchs et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Jnk signaling pathway-mediated regulation of Stat3 activation is linked to the development of doxorubicin resistance in cancer cell lines

(2009) Ju-Hwa Kim et al.   BIOCHEMICAL PHARMACOLOGY

Chemoprotection and enhancement of cancer chemotherapeutic efficacy of cyclophosphamide in mice bearing Ehrlich ascites carcinoma by diphenylmethyl selenocyanate

(2009) Pramita Chakraborty et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening

(2009) Piyush B. Gupta et al.   CELL

A Single Recombinant Adenovirus Expressing p53 and p21-targeting Artificial microRNAs Efficiently Induces Apoptosis in Human Cancer Cells

(2009) M. Idogawa et al.   CLINICAL CANCER RESEARCH

Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis

(2009) Eun-Woo Lee et al.   EMBO JOURNAL

Radiation Dose and Breast Cancer Risk in the Childhood Cancer Survivor Study

(2009) Peter D. Inskip et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular profile of breast versus ovarian cancer cells in response to treatment with the anticancer drugs cisplatin, carboplatin, doxorubicin, etoposide and taxol

(2008) Hellinida Thomadaki et al.   BIOLOGICAL CHEMISTRY

Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques

(2008) Yaohua Wang et al.   CANCER LETTERS

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

(2008) A. C. Mita et al.   CLINICAL CANCER RESEARCH

p21 and p27: roles in carcinogenesis and drug resistance

(2008) Abde M. Abukhdeir et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Death Receptor-Induced Activation of the Chk2- and Histone H2AX-Associated DNA Damage Response Pathways

(2008) S. Solier et al.   MOLECULAR AND CELLULAR BIOLOGY

Impairment of the DNA Repair and Growth Arrest Pathways by p53R2 Silencing Enhances DNA Damage-Induced Apoptosis in a p53-Dependent Manner in Prostate Cancer Cells

(2008) H.-L. Devlin et al.   MOLECULAR CANCER RESEARCH

WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: Identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers

(2007) Che-Jen Hsiao et al.   BIOCHEMICAL PHARMACOLOGY